[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-pancreatic-fluid-collection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-pancreatic-fluid-collection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100424911","prospective-registry-of-therapeutic-endoscopic-ultrasound-100424911",false,"NCT04813055","Prospective Registry Of Therapeutic EndoscopiC ulTrasound","PROTECT","Inclusion Criteria:\n\n* subjects candidate to therapeutic EUS (T-EUS) procedures for any underlying disease\n* subject eligible to T-EUS procedures but undergoing other non-EUS based endoscopic procedures, percutaneous or surgical procedures\n* 18 years old or older\n* able to provide an informed consent to inclusion.\n\nExclusion Criteria:\n\n* age \\\u003C 18 years\n* inability or unwillingness to sign the informed consent form (ICF)\n* contra-indication for endoscopy or use of fluoroscopy","ALL","18 Years",{"count":19,"type":20},510,"ESTIMATED","12 Months","OBSERVATIONAL","This registry aims to analyze long-term outcomes of therapeutic EUS (T-EUS) procedures, as well as to describe clinical and technical variables potentially predicting clinical success or adverse events, for a better selection of ideal candidates.\n\nThe study also includes standard alternatives to T-EUS procedures for outcomes comparison.",[25,26,27,28,29,30],"Gastric Outlet Obstruction","Biliary Obstruction","Acute Pancreatic Fluid Collection","Acute Pancreatitis With Infected Necrosis","Acute Cholecystitis","Chronic Pancreatitis",[32,33,34,35,36,37,38],"Endoscopic ultrasound","Therapeutic EUS","Interventional EUS","Biliary Drainage","Gastro-jejunostomy","Gallbladder Drainage","Endoscopy","RECRUITING","2026-04-10",{"date":42,"type":43},"2026-04-13","ACTUAL",{"date":45,"type":43},"2020-12-01",{"date":47,"type":20},"2026-12-31",{"name":49,"class":50},"Paolo Giorgio Arcidiacono, MD","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":51},"100580263","dextran-40-plus-ringers-lactate-vs-ringers-lactate-alone-for-fluid-resuscitation-in-acute-pancreatitis-100580263","NCT06835023","Dextran 40 Plus Ringer's Lactate Vs. Ringer's Lactate Alone for Fluid Resuscitation in Acute Pancreatitis","A Randomized Controlled Trial Evaluating Fluid Resuscitation in Acute Pancreatitis: Dextran 40 and Ringer's Lactate (1:3 Ratio) Versus Ringer's Lactate Alone","Inclusion Criteria:\n\n* adults (≥18 years) diagnosed with mild or moderate acute pancreatitis\n* must provide written informed consent for study participation.\n\nExclusion Criteria:\n\n* patients who decline to provide informed consent.\n* patients are non-compliant with treatment and follow-up visits.\n* pregnant individuals.\n* patients requiring concomitant treatment that is contraindicated within the study protocol.\n* patients who develop conditions that contraindicate the administration of the investigational medication.\n* patients experiencing severe adverse reactions necessitating treatment discontinuation.",{"count":60,"type":20},100,"INTERVENTIONAL",[63],"NA","This clinical trial aims to learn if a combination of Dextran 40 and Ringer's lactate solution can improve fluid resuscitation in mild and moderate acute pancreatitis (AP) and prevent complications. The main questions it aims to answer are:\n\nDoes early fluid resuscitation with Dextran 40 plus Ringer's lactate improve patient outcomes compared to Ringer's alone? Does this treatment reduce inflammation, organ failure, and the need for intensive care unit (ICU) admission? Researchers will compare Dextran 40 plus Ringer's lactate to Ringer's alone to see if the combination therapy is more effective in reducing disease severity and complications.\n\nParticipants will:\n\nReceive either Dextran 40 plus Ringer's lactate (1:3 ratio) or Ringer's lactate alone.\n\nHave blood tests every 24 hours to measure inflammation and organ function. Be monitored for changes in disease severity, need for ICU admission, and hospitalization duration.\n\nThis study will help determine the best fluid resuscitation strategy for treating mild and moderate acute pancreatitis.",[66,27,67],"Acute Pancreatitis (AP)","Fluid Resuscitation",[69,70,71,72,73],"Fluid resuscitation","Acute pancreatitis","Dextran","Ringer Lactat solution","combination colloid-crystalloid","2025-02-18",{"date":76,"type":43},"2025-02-20",{"date":78,"type":43},"2022-01-10",{"date":80,"type":20},"2025-05-12",{"name":82,"class":83},"Satu Mare County Emergency Hospital","OTHER_GOV"]